Study of Elderly Patients With Cancer and Seen in Consultation of Geriatric Oncology in the Nord Pas-de-Calais (CONSOG).

Cancer Clinical Trial

Official title:

Study of Elderly Patients With Cancer and Seen in Consultation of Geriatric Oncology in the Nord Pas-de-Calais (CONSOG).

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02501174
• Other study ID #: CONSOG-1401
• Status: Completed
• Start date: October 2014
• Est. completion date: September 2019

Study information

• Verified date: October 2021
• Source: Centre Oscar Lambret
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this study is to establish a common geriatric oncology medical database. The patients concerned are the patients having benefited from a geriatric oncology consultation in one of the participating centres. This database is designed with a view on the one hand to better describe to better understand this population and on the other hand to facilitate the conduct of future retrospective or prospective studies on this population. The constitution of this observatory of patients seen in consultation should facilitate the development of studies from the analysis of data collected, and occasional surveys by the rapid identification of cases. Data from this database could provide clinicians with valuable informative elements of descriptive epidemiology and concerning the organization of care in the geriatric oncology field.

Description:

The study is presented during the first consultation of oncogeriatric care or after this consultation (for patients having benefited from the consultation between January 2014 and October 2014) : the patient is informed with an information note and is told that he can express its opposition to the use of its clinical data. In case of no opposition from the patient, the referent geriatrician will complete the patient form with the requested data and will forward it for computerized processing.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2914
• Est. completion date: September 2019
• Est. primary completion date: September 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Patient seen in consultation of geriatric oncology in one of the participating centres in Nord Pas-de-Calais.

• Age = 65 years

• Patient having been informed and not opposing the computerized processing of its data.

Exclusion Criteria:

• Patient having opposed the use of its medical data.

Related Conditions & MeSH terms

• Cancer
• Neoplasms

Locations

Country	Name	City	State
France	Centre Hospitalier d'Arras	Arras
France	Centre Hospitalier	Béthune
France	Centre Hospitalier	Boulogne sur Mer
France	Centre Hospitalier, Douai	Douai
France	Centre Hospitalier	Dunkerque
France	Hospitalier Le Cateau-Cambresis	Le Cateau-Cambrésis
France	Polyclinique de Riaumont	Liévin
France	Centre Oscar Lambret	Lille
France	CHRU de Lille	Lille
France	Hôpital Saint Vincent de Paul	Lille
France	Hôpital Saint-Philibert	Lomme
France	Clinique Saint Jean, Roubaix	Roubaix
France	Centre Hospitalier	Tourcoing
France	Centre de cancérologie Les Dentellières	Valenciennes
France	Centre Hospitalier	Valenciennes

Sponsors (1)

Lead Sponsor	Collaborator
Centre Oscar Lambret

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measurement of the prevalence of different clinical criteria of interest : demographic characteristics, disease state, patient status according to the geriatric criteria (Comprehensive Geriatric Assessment (CGA)).		Up to 5 years
Secondary	Measurement of the prevalence of different medical and social criteria of interest.	Patient's life characteristics (place of living, isolation) and the helps set up (presence of a natural caregiver, sources of professional help).	Up to 5 years
Secondary	Measurement of the association between one or more factors of interest (clinical, biological and medical and social) related to a proposal to amend or not the initially proposed therapeutic strategy.		Up to 5 years
Secondary	Percentage of patients included in trials.		Up to 5 years
Secondary	Temporal evolutions of clinical, medical and social characteristics.		Up to 5 years